: The growing interest in natural and sustainable products has driven research into phenolic bioactive compounds, which are known for their antioxidant properties. Cashew residue extract emerges as a promising source of these compounds, with the potential to add value to agro-industrial by-products. This study aimed to develop and evaluate a nanoemulsion containing cashew residue extract, emphasizing its antioxidant activity and applications in pharmaceutical, cosmetic, and food products. The methodology included enzyme-assisted extraction, characterization of the extract for total phenolic content (Folin-Ciocalteu method) and HPLC, evaluation of antioxidant activities (DPPH, ABTS, hydroxyl radical, reducing power, and TAC), anti-inflammatory activity (nitric oxide reduction), cytotoxicity, cell migration, and proliferation. Subsequently, the nanoemulsion was prepared, with formulation optimization and 90-day stability monitoring under different conditions, analyzing droplet size, PDI, zeta potential, pH, conductivity, and in vitro antioxidant activity. Results showed high phenolic content in cashew residue extract (327 ± 2.99 μg/L GAE, higher than reported in the literature), identification of eight compounds by HPLC (with quantification of gallic acid, p-coumaric acid, ferulic acid, and quercetin), strong antioxidant activity (ABTS 93.16% ± 0.53%, DPPH 68.78% ± 2.55%, hydroxyl 95% ± 0.09%, reducing power 96.47% ± 0.09%, and TAC 5.20 ± 0.01 mg/g), low cytotoxicity (>80% cell viability), significant NO reduction at 50 and 100 μg/mL concentrations, and stimulation of cell migration/proliferation. The nanoemulsion exhibited excellent physicochemical stability for 90 days (especially under refrigeration), 95.9% ± 0.34% encapsulation efficiency, and superior performance compared to the pure extract in vitro antioxidant and anti-inflammatory activities. It is concluded that the cashew residue extract nanoemulsion shows promising potential as a candidate for innovative and sustainable cosmeceutical applications. Although ex vivo safety screening (HET-CAM) has been performed, future clinical trials in human volunteers are required to confirm its dermatological efficacy and safety in finished cosmetic products.
No takes yet. Share an insight, caveat, or question.
Sena et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: